JP2022502359A - 皮膚科障害の処置のための薬剤 - Google Patents

皮膚科障害の処置のための薬剤 Download PDF

Info

Publication number
JP2022502359A
JP2022502359A JP2021514556A JP2021514556A JP2022502359A JP 2022502359 A JP2022502359 A JP 2022502359A JP 2021514556 A JP2021514556 A JP 2021514556A JP 2021514556 A JP2021514556 A JP 2021514556A JP 2022502359 A JP2022502359 A JP 2022502359A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
ngf
use according
ulcers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502359A5 (https=
JPWO2020058217A5 (https=
Inventor
ヴィレッティ，ジーノ
インビンボ，ブルーノ・ピエトロ
カルツァ，ラウラ
Original Assignee
キエージ・フアルマチエウテイチ・エツセ・ピ・ア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キエージ・フアルマチエウテイチ・エツセ・ピ・ア filed Critical キエージ・フアルマチエウテイチ・エツセ・ピ・ア
Publication of JP2022502359A publication Critical patent/JP2022502359A/ja
Publication of JP2022502359A5 publication Critical patent/JP2022502359A5/ja
Publication of JPWO2020058217A5 publication Critical patent/JPWO2020058217A5/ja
Priority to JP2025077313A priority Critical patent/JP2025125558A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021514556A 2018-09-17 2019-09-17 皮膚科障害の処置のための薬剤 Pending JP2022502359A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077313A JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18194930.6 2018-09-17
EP18194930 2018-09-17
EP18203665.7 2018-10-31
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077313A Division JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Publications (3)

Publication Number Publication Date
JP2022502359A true JP2022502359A (ja) 2022-01-11
JP2022502359A5 JP2022502359A5 (https=) 2022-09-28
JPWO2020058217A5 JPWO2020058217A5 (https=) 2022-09-28

Family

ID=67989007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514556A Pending JP2022502359A (ja) 2018-09-17 2019-09-17 皮膚科障害の処置のための薬剤
JP2025077313A Pending JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077313A Pending JP2025125558A (ja) 2018-09-17 2025-05-07 皮膚科障害の処置のための薬剤

Country Status (11)

Country Link
US (2) US20220064243A1 (https=)
EP (1) EP3852785A1 (https=)
JP (2) JP2022502359A (https=)
KR (1) KR20210061388A (https=)
CN (1) CN113226350B (https=)
AU (1) AU2019343514B2 (https=)
BR (1) BR112021003820A2 (https=)
CA (1) CA3111158A1 (https=)
MA (1) MA53636A (https=)
MX (1) MX2021002983A (https=)
WO (1) WO2020058217A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (ja) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー Ｎｇｆバリアント、産生、組成物、及び治療的使用
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCESCA MALERBA ET AL., PLOS ONE, vol. Vol.10 No.9 (e0136425), JPN6023030947, 2015, pages 1 - 34, ISSN: 0005496443 *
FRANCESCO LANDI ET AL., ANNALS OF INTERNAL MEDICINE, vol. 139, no. 8, JPN6024016925, 2003, pages 635 - 641, ISSN: 0005496445 *
LUIGI ALOE ET AL.: "Nerve growth factor: from the early discoveries to the potential clinical use", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 10, JPN6024052591, 2012, pages 239 - 1, ISSN: 0005496446 *
S. GENERINI ET AL., EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol. 112, no. 9, JPN6024016926, 2004, pages 542 - 544, ISSN: 0005496444 *

Also Published As

Publication number Publication date
BR112021003820A2 (pt) 2021-05-25
AU2019343514A1 (en) 2021-04-15
CA3111158A1 (en) 2020-03-26
EP3852785A1 (en) 2021-07-28
JP2025125558A (ja) 2025-08-27
KR20210061388A (ko) 2021-05-27
MA53636A (fr) 2021-12-22
AU2019343514B2 (en) 2025-09-25
CN113226350B (zh) 2024-09-10
MX2021002983A (es) 2021-05-14
WO2020058217A1 (en) 2020-03-26
US20220064243A1 (en) 2022-03-03
CN113226350A (zh) 2021-08-06
US20250277010A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
US20250277010A1 (en) Agent for treatment of dermatological disorders
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
CN109535243B (zh) 人肝细胞生长因子突变体及其应用
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
US20210038690A1 (en) Promoting epithelial regeneration using heparin binding epidermal growth factor like growth factor
CN100509055C (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
JP2025122021A (ja) 抗炎症剤
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
CN106488773A (zh) Apc类似物用于创伤愈合的用途
HK40047629A (zh) 皮肤病治疗剂
JP2024532086A (ja) 炎症性疾患の処置のためのタンパク質組成物
HK40047629B (zh) 皮肤病治疗剂
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
JPWO2000078338A1 (ja) 膀胱平滑筋の受動的伸展を促進するための組成物
JP2008507559A (ja) ２０ｋＤａ胎盤成長ホルモン変種を使用した糖尿病非誘発性療法
JPWO1999064058A1 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107